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The Project on a Framework for Rating Evidence in Public Health (PRECEPT) is an international 
collaboration of public health institutes and universities which has been funded by the European 
Centre for Disease Prevention and Control (ECDC) since 2012. Main objective is to define a 
framework for evaluating and grading evidence in the field of public health, with particular focus on 
infectious disease prevention and control. As part of the peer review process, an international expert 
meeting was held on 13-14 June 2013 in Berlin. Participants were members of the PRECEPT team and 
selected experts from national public health institutes, World Health Organization (WHO), and 
academic institutions. The aim of the meeting was to discuss the draft framework and its application 
to two examples from infectious disease prevention and control. This article introduces the draft 
PRECEPT framework and reports on the meeting, its structure, most relevant discussions and major 




1. Introduction   
The Project on a Framework for Rating Evidence in Public Health (PRECEPT) has been funded by the 
European Centre for Disease Prevention and Control (ECDC) since 2012. Main objective is to define a 
framework for evaluating and grading evidence in the field of infectious disease prevention and 
control. As part of the peer review process, an international expert meeting was held on 13-14 June 
2013 in Berlin. Participants were members of the PRECEPT team and selected experts from national 
public health institutes, World Health Organization (WHO), and academic institutions. The aim of the 
meeting was to discuss the draft framework and its application to two examples from infectious 
disease prevention and control, which were prepared in advance by team members.  
PRECEPT was able to build on the work of an ECDC working group, which evaluated the 
methodology of the Grading of Recommendation, Assessment, Development, and Evaluation 
(GRADE) Working Group and proposed further discussion of GRADE for application in the context of 
public health, particularly regarding infectious diseases [1]. It was therefore decided that GRADE will 
be a key component of PRECEPT, and applying the method to interventional and non-interventional 
studies is being tested within the project.  
According to GRADE, the quality of evidence indicates the extent to which one can be 
confident that the estimate of effect is correct [2]. GRADE assesses the overall quality of evidence 
supporting a recommendation across outcomes, which considers the quality rating of all outcomes 
critical for decision-making. One of four levels of evidence quality is assigned to the review results. 
Bodies of randomized controlled trials (RCTs) are initially graded as high quality of evidence, whereas 
bodies of observational studies are initially classified as low quality. Considering a set of criteria 
might lead to decreasing (downgrading) or increasing (upgrading) one’s confidence by one or more 
levels based on the critical appraisal of the body of evidence related to the outcome under 
consideration [2]. 
After an introduction to the PRECEPT framework and the meeting structure, we report the 
most relevant discussions and major conclusions.    
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2. The draft PRECEPT framework: overview 
The PRECEPT framework – as currently proposed- is intended to rate scientific evidence related to 
four domains of questions: disease burden, risk factors, diagnostics and interventions. The 
framework is scheduled into six consecutive steps, from question framing to evidence statement.  
In step one, tools are provided to identify key questions relevant for decision-making. 
Drawing on systematic reviews performed in step two, guidance is provided on the choice of quality 
appraisal tools (QATs) for assessment of individual studies. An algorithm is given to match a given 
study design with an appropriate QAT (step three). The set of QATs suggested here has been 
identified during a review performed by the study team [3]. In step four, a generalized evidence 
grading based on GRADE is provided to rate the quality of the bodies of evidence. In this step, 
approaches previously discussed and proposed by the GRADE Working Group [4, 5] or WHO [6, 7] are 
applied. The latter is used by the WHO Strategic Advisory Group of Experts (SAGE) for the 
development of vaccination recommendations and includes a modification of the GRADE 
methodology which allows uprating of evidence quality in the presence of “consistency across 
investigators, study designs and settings” [7]. For qualitative studies, an approach under discussion 
by the GRADE Working Group is proposed [8]. The evidence appraisal process ends with the 
preparation of evidence profiles and summary of findings tables (see [9, 10] for examples) (step five), 
followed by the preparation of evidence summary statements (step six) (Figure 1). By applying this 
framework, the user should be able to evaluate and grade scientific evidence within the four 
domains described above in a transparent and reproducible way.   
 
3. Structure of the meeting 
Following presentations about the framework and on the application of GRADE to public health, two 
working groups (WGs) were formed to discuss the draft framework (WG1: from step “framing of 
questions” to “systematic review”; WG2: from step “quality appraisal” to “evidence summary”), 
guided by a set of prepared key questions. Participants also split into two WGs to test how different 
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bodies of evidence from interventional as well as non-interventional studies can be appraised by the 
framework, using two case studies (WG3 and WG4).   
 
4. Challenges in the application of GRADE to public health  
In Randy Elder´s keynote presentation, challenges when applying GRADE to public health were 
discussed. Two types of challenges were identified. The first one relates to scarcity of evidence from 
RCTs to address specific public health questions.  The second one relates to validity, suggesting that 
for several public health questions GRADE assessments of evidence quality might be biased and 
underestimate the true quality of the evidence. For example, studies which measured changes in 
influenza vaccination coverage attributable to worksite programs [11, 12] received only a 
“moderate” evidence quality rating according to GRADE. Taking into account factors that are not 
considered in GRADE ratings, such as the consistently observed step-function increase in vaccination 
coverage when these programs were implemented, a “high” quality rating would better reflect the 
true risk that the apparent intervention effects were spurious. Additional examples for community-
based interventions were presented, where, according to the speaker, GRADE ratings might not 
adequately reflect the quality of the evidence derived from specific types of non-randomized studies, 
such as interrupted time series performed in different settings by different investigators during 
different time periods demonstrating similar effects [13]. It was therefore proposed that non-
randomized designs which are less prone to bias such as a body of interrupted time series should 
already initially be judged in the GRADE system as being of “moderate” quality. Furthermore, the 
question was raised whether upgrading of evidence quality might be appropriate when the overall 
pattern of evidence across settings or study designs mitigates otherwise plausible threats to validity.  
 
5. Summary of discussions: From framing the questions to systematic reviews  
The WG suggested revising the framework’s domains, including incorporation of additional domains 
(e.g., “preferences and values”, “cost-effectiveness”). Regarding question framing, it was proposed to 
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use the PI(E)CO framework (P- Population, I – intervention or E- exposure, C – comparator, O – 
outcome) as standard, and to integrate other questions – especially for domains not related to 
interventions –  as far as possible. Furthermore, the development of a logic model or “conceptual 
framework”, that visualizes the interconnectedness between e.g. risk factors, disease, hospitalization 
rate and intervention, can be useful to identify relevant questions (for details, see [14]).  
The WG proposed that qualitative studies, relevant not only because of their importance for 
decision-making processes, should not be handled as a separate domain (as suggested in the initial 
framework proposal), but where appropriate should be integrated in the domains as one of several 
research designs. Regarding the applicability of GRADE to qualitative studies, the WG concluded that 
some of the GRADE criteria appear applicable (i.e., indirectness). However, this remains unclear for 
other GRADE criteria (i.e., imprecision), leaving an area for methods development currently explored 
by the working group.  
 
6. Summary of discussions: From quality appraisal to evidence summary 
For quality appraisal of individual studies, PRECEPT provides a selection of QATs according to study 
design. The WG concluded that a flowchart is useful to identify the appropriate QAT(s) for a given 
study design. However, caution is needed when different QATs are used because some are checklists 
whereas others produce overall quality ratings. It is therefore necessary to interpret the result of the 
quality appraisal process as a considered judgment, rather than a score, when assigning a quality 
label to an individual study.     
Regarding the applicability of GRADE to domains other than interventions, the group 
concluded that its application is in principle possible, and that GRADE criteria for downgrading could 
be applied to all four domains.   
For the domains “risk factors” and “interventions” some participants suggested introducing 
an additional upgrading criterion “consistency across settings and study designs” [6]. Even though 
intuitively this criterion looks similar to the downgrading criterion “inconsistency”, a number of 
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participants found this to be a useful and important criterion that embraces the concept of 
complementary evidence, which entails more than just the opposite of inconsistency. That is, 
whereas in the GRADE approach “inconsistency” refers to heterogeneity of effect measures for a 
given outcome [15], “consistency across settings and study designs” means that consistent results 
have been obtained under a variety of conditions (study design and setting), which might increase 
confidence in the overall assessment unless it has to be assumed that an unmeasured confounder 
influenced the results in all settings in a similar way.    
 
7. Case study I: Introduction of routine rotavirus vaccination of infants in a population 
Case study I focused on the question whether routine rotavirus vaccination for infants should be 
introduced in a specific country and was based on a recently developed recommendation for 
Germany [10]. The aim was to test the applicability of PRECEPT to grade the available evidence 
related to local disease burden (or baseline risk) and disease perception. The WG suggested that the 
particular QAT must be able to account for problems of data quality in different study designs, which 
are inherent to active vs. passive surveillance systems. Underestimation (as well as overestimation) 
of disease rates in surveillance systems can be conceptualized as risk of bias and could be estimated 
through specific studies (e.g. capture-recapture studies). Observational evidence from both active 
and passive surveillance would enter the GRADEing procedure initially as high quality and should 
then be downgraded if e.g. a risk of bias is identified. In respect to the systematic literature search it 
was highlighted by the group, that especially for incidence studies there is often evidence from non-
peer-reviewed, “grey-literature” sources such as national disease reporting systems that needs to be 
identified through specific search strategies. 
The WG concluded that in principle it is possible to assess bodies of evidence on disease 
incidence/prevalence, utilizing the GRADE approach [4]. With regard to the GRADE criterion of 
“inconsistency”, differences in incidence/prevalence data might be explainable by regional 
differences or temporal trends. It should then be discussed whether it is appropriate to downgrade 
9 
 
evidence quality. In addition, incidence estimates might differ inherently between studies due to 
their design (active vs. passive case ascertainment). In such situations, one would rather present 
separate results for the different regions/times/designs.  
The WG also concluded that publication bias is important with regard to 
prevalence/incidence studies because of factors such as pharmaceutical industry interests, in 
addition to publication practices. WG participants suggested that publication bias in 
prevalence/incidence studies might be detected by stratification of findings by source of funding.  
  
8. Case study II: Spread of carbapenemase-producing Enterobacteriaceae 
Case study II dealt with the spread of carbapenemase-producing Enterobacteriaceae and was based 
on an ECDC Technical Report [16]. The aim was to test the applicability of PRECEPT to questions 
related to risk factors and complex interventions. The WG suggested that risk factor studies might in 
general start as “high quality” of evidence. Thereafter, GRADE criteria would be applied to the 
respective body of evidence for downgrading, but details remain to be worked out in close 
collaboration with the GRADE Working Group. 
Regarding complex interventions, it is not sufficient to appraise the quality of a body of 
evidence on a complex intervention with multiple optional components as such. Rather, details on 
the intervention components must be provided (e.g. in a matrix).  
 
9. Conclusions 
The following points summarize the most important meeting results: 
• Overall, the participating experts found the proposed PRECEPT framework very helpful and 
an important step forward in the development of a framework for evidence grading in the 
area of infectious disease prevention and control.  
• It was highlighted that PRECEPT should not be considered as an alternative to GRADE, but 
rather as a comprehensive framework to help provide guidance in infectious disease 
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prevention and control decision-making, in which GRADE is integrated as an important 
component.  
• Identifying and formulating the correct questions is the first and most important step in an 
evidence rating framework. The PI(E)CO approach should be the standard for framing of 
questions, and questions not related to interventions should be integrated as far as possible. 
Identification of relevant questions can be supported by construction of a logic model or 
“conceptual framework”.  
• Appropriate QATs should be used to assess risk of bias in individual studies, but the results of 
the appraisal process should be interpreted as a considered judgment.  
• GRADE can be successfully applied to bodies of evidence on incidence/prevalence, based on 
the approach published by the GRADE Working Group. 
• Risk factor studies should enter the GRADE-system initially as “high quality” of evidence. 
Thereafter, GRADE criteria for downgrading and upgrading should be applied, but details 
remain to be worked out in collaboration with the GRADE working group. 
• For the application of GRADE to the domains “risk factors” and “interventions”, meeting 
participants suggested to further discuss whether upgrading of the evidence quality should 
be allowed for “consistency across settings and study designs”. 
• GRADE can be successfully applied to evidence on complex interventions; details on the 
intervention components should be provided.  
• Qualitative studies are important at various stages, but should not be handled as a separate 
domain but as a study design to address given research questions e.g. related to values and 
preferences. Their quality should be appraised by QATs in the same manner as quantitative 
studies. Further research is needed regarding the applicability of the GRADE methodology to 
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Figure 1: Flow chart of the PRECEPT methodology 
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